There has been only marginal improvement in guideline-directed medical therapy uptake and mortality for US Veterans with recent-onset HFrEF from 2013 to 2019, highlighting an urgent need for new implementation strategies.
Answers are grounded in this paper and cite their sources.
Persistent gaps in GDMT uptake and survival for recent-onset HFrEF; leaves open whether targeted implementation strategies can accelerate gains.
This study found only marginal improvement between 2013 and 2019 in the guideline-recommended therapy and mortality rates among patients with recent-onset HFrEF. New approaches to increase the uptake of evidence-based HFrEF treatment are urgently needed and could lead to larger reductions in mortality.
No takes yet. Share an insight, caveat, or question.
Sandhu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: